|
Daehan New Pharm joins the development of a Tamiflu generic
2009.11.03
|
|---|
|
Daehan New Pharm Accelerates Development of Tamiflu Generic (Oseltamivir Capsules)
Daehan New Pharm Co., Ltd. (CEO Bae Gun-woo) has begun full-scale development of a generic version of “Tamiflu,” the antiviral medication for H1N1 influenza, under the product name Daehan New Pharm Oseltamivir Capsules.
The company explained that, given the growing public anxiety over H1N1 influenza and the rapid increase in infections and fatalities, this initiative is intended as a precautionary measure in anticipation of a potential compulsory license in the future.
To this end, the company signed a clinical testing agreement with BioSuntech Co., Ltd., a certified clinical research institution, for the Tamiflu generic, and submitted a bioequivalence study plan to the Korea Food and Drug Administration on the 3rd.
Earlier, in August, Daehan New Pharm also signed a five-year supply contract with PharmSwell Bio Co., Ltd., which has the capability to manufacture the active pharmaceutical ingredient (API) for the H1N1 treatment — oseltamivir phosphate, the raw material for Tamiflu. |


Home